Abingdon Health plc (LON:ABDX), a manufacturer of lateral flow diagnostic tests, has entered into a strategic partnership agreement with in vitro diagnostics specialist Senzo Health Limited, the two companies announced on Monday.

Under this agreement Abingdon Health will provide contract development and manufacturing (CDMO) services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilising Senzo's Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology.

Senzo's lateral flow technology is designed to deliver the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost.

It is initially being applied to the development of a COVID-19 antigen assay, a broader respiratory panel and other infectious disease tests, with potential future applications across clinical, animal health, food, plant pathogen and environmental testing. The new partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.